In addition to nanobodies, other nanoscale compounds, such as a copper (II) agent based on human serum albumin and a rhodium (III) complex delivered via apoferritin,[37] have been shown promise in overcoming drug resistance of NSCLC. The gene discussed is ALB; the disease is non-small cell lung carcinoma.